Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive Top-Line Results From Phase 3 RUTHERFORD-2 Trial Of Evolocumab (AMG 145) In Patients With Heterozygous Familial Hypercholesterolemia

[PR Newswire] – THOUSAND OAKS, Calif., Jan. 30, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the Phase 3 RUTHERFORD-2 ( R ed U ction of LDL-C with PCSK9 Inhibi T ion in . . . → Read More: Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive Top-Line Results From Phase 3 RUTHERFORD-2 Trial Of Evolocumab (AMG 145) In Patients With Heterozygous Familial Hypercholesterolemia Similar Articles: Company Update – Wells Fargo & Company (NYSE:WFC) – Range Resources operations update positive, says Wells Fargo Amgen Inc. (NASDAQ:AMGN) ~ Amgen announces MENDEL-2 Phase 3 trial met co-primary endpoints AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial